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Abstract
Background: Gene expression analysis has emerged as a major biological research area, with real-
time quantitative reverse transcription PCR (RT-QPCR) being one of the most accurate and widely
used techniques for expression profiling of selected genes. In order to obtain results that are
comparable across assays, a stable normalization strategy is required. In general, the normalization
of PCR measurements between different samples uses one to several control genes (e.g.
housekeeping genes), from which a baseline reference level is constructed. Thus, the choice of the
control genes is of utmost importance, yet there is not a generally accepted standard technique for
screening a large number of candidates and identifying the best ones.
Results: We propose a novel approach for scoring and ranking candidate genes for their suitability
as control genes. Our approach relies on publicly available microarray data and allows the
combination of multiple data sets originating from different platforms and/or representing different
pathologies. The use of microarray data allows the screening of tens of thousands of genes,
producing very comprehensive lists of candidates. We also provide two lists of candidate control
genes: one which is breast cancer-specific and one with more general applicability. Two genes from
the breast cancer list which had not been previously used as control genes are identified and
validated by RT-QPCR. Open source R functions are available at http://www.isrec.isb-sib.ch/
~vpopovic/research/
Conclusion: We proposed a new method for identifying candidate control genes for RT-QPCR
which was able to rank thousands of genes according to some predefined suitability criteria and we
applied it to the case of breast cancer. We also empirically showed that translating the results from
microarray to PCR platform was achievable.
Background
Real-time quantitative reverse transcription PCR (RT-
QPCR) has become a method of choice for gene expres-
sion profiling in a large number of applications. However,
obtaining reliable measurements still depends on the
choice of control genes on which the baseline level is con-
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point in the normalization process. Often, a short list of
candidates is produced based on non-systematic and/or
often poorly defined biological considerations.
In early studies, normalization was usually based on a sin-
gle control gene. More recently, the trend is to use several
control genes whose average expression level (on a log-
scale) is used as baseline [1,2]. Suitable control genes are
selected from a short list of 10–15 genes by ranking them
according to a criterion that essentially selects those genes
having low variation across samples. We describe brie y a
few such methods below.
[2] introduces a stability coefficient which is used along
with the coefficient of variation for ranking the genes
from a predefined list of candidates. Gene stability is
defined in terms of average standard deviation of the log-
ratios of pairs of candidate genes. Genes are ranked by
iteratively removing those most unstable. This approach
has the drawback that repeated comparison of pairs of
genes is required, which is feasible only when the number
of candidates is small. In addition, the method implicitly
assumes that there are no co-regulated genes. A model-
based approach proposed by [1] aims at estimating the
overall variation as well as the between sample variation
of each candidate gene. However, with this approach it is
cumbersome to integrate different platforms. In an appli-
cation to plant pathogen profiling, [3] investigates a list of
18 pre-selected candidate housekeeping genes, using the
method proposed in [2] and RT-QPCR for measuring the
gene expressions. [4] proposes a PCA-based statistical
analysis to identify the most suitable control genes among
13 candidates which were selected such that they had
independent functions in cellular maintenance.
[5] introduces a strategy which combines the coefficient of
variation, maximum fold change and mean expression
value in a ranking criterion that is applied to a large
number of samples representing a wide variety of tissues.
All these samples were hybridized on either Affymetrix
HG-U133A or HG-U133 Plus 2.0 arrays and quantile-nor-
malized together prior to ranking. Only probesets com-
mon to both arrays were used, with probesets targeting the
same gene averaged into a single value.
There are some important differences between the meth-
ods described above and our approach (described below).
Firstly, in contrast with all the studies based on PCR, we
do not require a short list of candidate genes to be pro-
duced before assessing their suitability as control genes.
Instead, we screen all the genes represented on the micro-
array chips, giving us the opportunity to assess genes that
have not been reported previously. Moreover, we take a
meta-analytical approach to the problem, first creating an
independent ranking within each data set then aggregat-
ing these rankings into a single list. This approach has the
advantage of being platform- and normalization-inde-
pendent. In addition, the approach is not limited to using
only genes common between different data sets. Also, by
not using the coefficient of variation, we can treat uni-
formly both single and two-colors arrays. Thus, we are
able to exploit data obtained from different platforms
without requiring them to be normalized together. Fur-
thermore, the meta-analytical approach allows us to inte-
grate gene lists produced using our ranking system with
other ranked gene lists from the literature and we do not
require all data to be normalized together. Another key
difference is that we introduce a new stability coefficient
that combines the mean expression and the standard devi-
ation in a ranking criterion that corresponds to our
requirements for candidate control genes for RT-QPCR. In
general, these requirements are:
• low variability across different specimens (e.g., subtypes
of tumors or normal tissues);
• high and moderate level of expression, such that control
genes with expression levels across a larger range may be
selected;
• consistency across experiments and platforms.
A key question is whether it is possible to select genes
from microarray studies that perform as control genes on
PCR platform, given that the two technologies are differ-
ent. We hypothesize that translating the list of candidate
genes from microarray to PCR platform is feasible and we
provide empirical evidence in this sense.
Results
Data sets and pre-processing steps
We have collected ten publicly available data sets [6-15],
listed in Table 1, from which we derived the quantities of
interest: the mean and standard deviations of the log-
Table 1: The ten public microarray data sets used (n = number of 
samples).
Data set ID and reference n Platform
BWH [6] 47 Affymetrix U133v2
EMC [7] 286 Affymetrix U133A
EXPO [8] 1375 Affymetrix U133Plus2
JRH2 [9] 61 Affymetrix U133A
MGH [10] 60 Agilent
NKI [11] 337 Agilent (custom)
STOCK [12] 159 Affymetrix U133A, B
TGIF1 [13] 49 Affymetrix U133A
UNC [14] 153 Agilent HuA1
UPP [15] 249 Affymetrix U133A, BPage 2 of 10
(page number not for citation purposes)
BMC Bioinformatics 2009, 10:42 http://www.biomedcentral.com/1471-2105/10/42intensities (on Affymetrix platforms) or of the log-ratios
(on Agilent platforms).
We note here that the original EXPO data set contains a
number of different pathologies, but we restrict analysis
here to eight different types of cancer (breast, colon,
endometrium, kidney, lung, ovary, prostate and uterus)
for which a sufficient number of samples existed. EXPO
breast cancer samples (n = 328) were used to produce
both the breast cancer and general cancer lists of candi-
date genes.
The Affymetrix data are available as MAS5.0 normalized
values. The Agilent data contains log-ratios (base 10) and
mean-centered log-intensities. The standard deviations of
log-intensities (Affymetrix) and log-ratios (Agilent) were
used as measures of variability. The means of log-intensi-
ties (both Affymetrix and Agilent) were used as measures
of average expression level.
When multiple probesets of the same gene are present,
only the most variable one is used. We consider all genes
from each platform, the aggregation methods used being
able to cope with 'missing' genes (those not represented
on the array). Considering only those genes common to
all platforms is an unnecessary limiting constraint, as
increasing the number of data sets and the heterogeneity
of the collection leads to a successively smaller intersec-
tion of genes.
Before any further usage of the data, we reduce the varia-
bility across platforms by scaling with a factor given by a
first order LOESS fit of the data. The effect of this transfor-
mation can be seen in Figure 1, where the black line rep-
resents the fitted curve. This simple approach seems
effective, except for genes with low expression. However,
as we are interested in genes with higher mean expression,
this deficiency is not problematic.
Ranking the genes
Let us consider that we have M microarray data sets, each
containing expression values of a set of genes Gk, k =
1,...,M, and let G = ∪kGk = {1,...,N} be the set of all genes
represented at least once in any of these data sets.
Example of variance stabilization by LOESS correctionFigure 1
Example of variance stabilization by LOESS correction. LOESS correction applied to three data sets: BWH, NKI and 
EXPO-breast, respectively. The first row shows the original data with the fitted first order LOESS curve, while the second row 
shows the variance-stabilized data.Page 3 of 10
(page number not for citation purposes)
BMC Bioinformatics 2009, 10:42 http://www.biomedcentral.com/1471-2105/10/42Gene scores
We aim to design a scoring function which ranks the genes
such that higher scores correspond to genes that are more
suitable to be used as control genes. As mentioned above,
the score has to combine each gene's mean expression and
standard deviation into a single value such that higher
expression levels and lower variances (standard devia-
tions) are favored. Moreover, the score must be independ-
ent of the technology used to measure expression levels
and the method for normalization.
These requirements lead us to propose a new stability score
for the gene expression levels. This score for gene i in data
set k, denoted sik, is defined as
where  and  are the estimated mean log-intensity
and the standard deviation of the gene i in data set k. The
 coefficient allows the user to control the trade-off
between the mean expression and the standard deviation
in gene scoring. Results reported here were obtained with
 = 0.25. The k parameter allows one to define the level of
mean expression below which the genes are not consid-
ered for ranking, i.e. the score for these genes is -∞. We
have set k to be the 25th percentile of the mean expres-
sion, for each data set k. Genes having a higher score are
considered more suitable as control genes. As we see from
Eq. 1, high variation in gene expression leads to a lower
score when mean expression levels are equal. This is one
reason we select the most highly variable probeset from
the probesets representing the same gene, in order to
encompass the worst-case scenario. Note also that there is
no need to normalize the scores to make them compara-
ble across data sets, because they are used solely for rank-
ing the genes within the same data set. Finally, having
computed the scores for all the genes within a data set, we
order the genes from high to low values of the scores, with
ties resolved by ordering by the mean expression (from
high to low). From this perspective, the scores can be seen
as defining classes of equivalence among genes: all the
genes in the same class (having the same score) are
equally useful as normalization genes. By using the sec-
ond ordering criterion, we can select control genes with a
desired expression level (examples of classes of equiva-
lence are the equal score levels in Figure 2).
Figure 2 displays the influence of the mean expression
level and the standard deviation on the gene score. All
genes located on the curves have the same score value
(they belong to the same equivalence class). Two consec-
utive curves are separated by one score unit.
Using this stability score, we ranked the genes from each
data set, obtaining the lists that will be later combined. An
excerpt from the ten lists for the breast cancer data sets is
shown in Table 2 (first ten columns).
Combining results from different data sets
Once genes are ranked according to their scores in each
data set (lower ranks correspond to higher scores), the
natural next step is to combine these rankings into a glo-
bal ranked list. We combine the ranks of the genes rather
sik ik k ik= − −a m b slog (max{ , }) ,2 0 (1)
mˆ ik sˆ ik
Scatter plots of standard deviation versus mean log-intensity for BWH, NKI and EXPO-breast data sets, respectivelyFigure 2
Scatter plots of standard deviation versus mean log-intensity for BWH, NKI and EXPO-breast data sets, 
respectively. The shading codes the gene stability scores, with darker colors indicating higher scores. These three data sets 
are from different microarray platforms. The light gray points indicate the discarded genes (those with mean expression level 
below the  value – see Eq. 1). The curves correspond to equal score levels and are one score unit apart.Page 4 of 10
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different data sets, thereby achieving platform-independ-
ence. To this end we use the rank product score [16], which
is a fast and efficient method for combining ranked lists.
It computes, for each gene i ∈ G, a new score
where rankk(i) is the rank of sik, the score for gene i in data
set k (topmost gene has the rank 1), and ni is the number
of data sets in which the gene i appears. The final list is
obtained by sorting the genes in increasing order of Ri. The
top 20 genes from the aggregated breast cancer list are
given in the 'Meta' (last) column of Table 2.
Validation of the aggregated lists
There is no absolute criterion by which one can judge the
quality of the resulting lists. Rather, the aggregated list
could be used to select from the top genes (100, for exam-
ple) those genes that also satisfy further conditions of the
specific application.
We can, however, have a subjective impression of the
validity of the aggregated list by visualizing the resulting
top genes in data sets not used for producing the list. We
obtained a list of the top 100 genes by applying the
method described above on eight of the ten data sets, leav-
ing NKI and UPP aside as validation sets. The top 100
genes in both validation sets (different microarray plat-
forms) are plotted in Figure 3. As a comparison, we also
include the five control genes used in [17] (represented as
triangles in the figure). It is seen that the genes are gener-
ally concentrated in the lower right part of the plot, corre-
sponding to high mean expression levels and low
variance. There is a notable difference between the quality
of the results (given by the concentration of the control
genes in the lower right corner) on the two platforms, due
to the fact that most of the data sets used for gene selection
are from Affymetrix platforms. While the top 100 lists
contain genes with high stability scores on the Affymetrix
platforms (the UPP data set), on the custom Agilent plat-
form (NKI) there are a number of genes that are missed.
Nevertheless, those selected still function well as control
genes.
Control genes lists
We have analyzed ten different data sets which have sam-
ples hybridized on different versions of Agilent and
Affymetrix platforms. Using our proposed method, we
compiled two different lists of candidate control genes:
one specific to breast cancer [see Additional file 1] and
one resulting from the analysis of eight different types of
cancer, thus applicable to cancers in general [see Addi-
tional file 2]. From the breast cancer list we selected two
new control genes which were validated in an RT-QPCR
assay that also included five previously used control genes
(ACTB, TFRC, GUSB, RPLP0 and GAPDH – see [17]) and
breast cancer-related genes (e.g. ESR1, ERBB2, AURKA,
etc.). The RT-QPCR results confirm the findings from the
microarray analysis and show that more stably expressed
control genes can be selected by applying the criteria men-
R i
ni
i k
k
=
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟∏ rank ( ) ,
1
(2)
Table 2: Top 20 control genes from the ten breast cancer data sets and top 20 genes from the aggregated list (Meta column)
BWH EMC JRH2 MGH NKI STOCK TGIF1 UNC UPP EXPO-breast Meta
RPL37A PPIA RPL41 ZNF557 UBC RPS11 RPL41 RPS10 RPL9 CALM2 RPL37A
RPL41 CALM2 RPL39 CDR1 UBB RPS24 RPL37A RPS18 RPL37A HNRPA1 RPL27A
RPS18 SRP14 RPL23A PPP1R2 OAZ1 RPL9 EEF1A1 RPLP1 ACTG1 NACA RPS18
RPL39 RPL37A RPL37A TCN2 DYNLL1 RPL37A RPL30 RPS11 RPL27A UBA52 RPL30
RPL23A RPS18 EEF1A1 SSBP1 RAPSN RPL41 RPL39 RPS23 CFL1 LAPTM4A RPL41
RPL9 RPL30 RPS23 RPL27A PCBP1 RPL27A PPIA RPL37A RPS11 RPL27A CALM2
RPLP1 RPL27A RPS27 RPS3 KCNH3 RPL39 ACTG1 RPL11 RPS13 RPL30 RPL27
RPS27 RPS11 CALM2 BRCC3 RPL3 RPLP1 CFL1 RPS15 RPL27 RPL9 K-ALPHA-1
RPL27A RPL39 RPS18 PTMA RPL8 UBB RPS23 RPL14 RPL41 RPL31 RPS11
RPL30 RPS15 ACTG1 ABCF2 MYL6 RPS15A RPL10 NACA RPS18 RPL37 RPL39
RPS29 RPS24 RPL10 PCDH18 RPL14 CALM2 CALM2 RPL36AL RPS15 RPS11 RPS13
ACTG1 RPL32 RPS24 LAX1 RPL7A NACA RPS11 UBA52 RPL6 RPS29 NACA
CALM2 RPS15A RPS15A TPMT FAU RPL30 HNRPA1 NEDD8 RPLP1 RPS24 RPL23A
RPS13 RPLP1 RPL32 GALE ARF1 CFL1 RPL6 PCBP1 RPL32 RPS13 RPS24
HNRPA1 RPL9 RPL27A MTCH1 CCT3 RPS13 RPL23A NDUFB2 RPL31 RPS21 HNRPA1
RPS24 UBB UBB ATP5G2 PSAP RPS3A K-ALPHA-1 HNRPM RPL39 UBB RPL9
RPL31 K-ALPHA-1 RPS29 SF3B2 CD81 RPL37 RPS18 HNRPC UBB RPS27A RPLP1
RPL34 RPS13 RPL30 SND1 SQSTM1 RPS18 EEF1G NDUFB8 RPS24 RPS15 RPL32
RPS15A RPL27 PPIA RPL5 K-ALPHA-1 RPL27 TUBA6 ATP5J2 RPS27 RPL32 LAPTM4A
RPS21 FAU CFL1 SKAP2 CALR RPL24 RPS3A TARDBP DDX5 RPL24 RPS15APage 5 of 10
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porting the working hypothesis that PCR control genes
can be selected from microarray data.
The list of the top 50 control genes obtained from the ten
breast cancer data sets is given in Table 3. More compre-
hensive lists, including one containing the top 2000 can-
didate breast cancer genes and a similar list compiled
from eight different types of cancer, are available [see
Additional file 1 and Additional file 2]. In the case of
breast cancer control genes, it is interesting to note that
some of the "classical" genes (e.g. ACTB, GAPDH, TFRC)
are not among the top 50.
Evaluation of control genes by RT-QPCR
Motivated by the consistency of the selection process for
suitable control genes among different microarray plat-
forms, we performed a small scale RT-QPCR experiment
to test the performance of two new control genes along
with a number of more commonly used control genes. In
this experiment, RNA was isolated from 25 cryo-preserved
breast cancer samples and the expression of 47 genes was
measured by RT-QPCR [18]. Test genes were selected
according to their relatedness to proliferation or estrogen
receptor functions. Some of the test genes had been previ-
ously identified and used for characterizing primary
breast cancers [17]. Two genes, RPS11 and UBB, ranked 9
and 31 in Table 3 respectively, were compared to five
additional control genes and to a number of test genes
previously measured by [17]. Mean raw expression values
of all candidate control and test genes were plotted against
standard deviations of each gene (Figure 4). The raw Ct
(cycle threshold) value is the number of PCR cycles
required for the fluorescence signal to cross the back-
ground threshold, so that low Ct values correspond to
high expression levels. RPS11 and UBB are clearly among
the most stably expressed genes, as their standard devia-
tions are both quite low. Other genes frequently used as
control genes are also shown. For comparison, mean
expression and standard deviation of several test genes are
also indicated. The expression of most test genes is much
more variable than UBB and RPS11.
The two new control genes, together with RPLP0, offer the
best trade-off between mean expression level and variabil-
ity, while others like ACTB or TFRC are less stably
expressed and therefore seem less suitable for use as nor-
malization genes.
Discussion
We propose a new approach which leverages publicly
available microarray data to produce lists of candidate
control genes for RT-QPCR. Our method is independent
of the microarray platform or normalization methodol-
Scatter plots of standard deviation versus mean log-intensity for two validation data sets (from left to right: NKI and UPP)Figure 3
Scatter plots of standard deviation versus mean log-intensity for two validation data sets (from left to right: 
NKI and UPP). The top 100 breast cancer control genes resulting from aggregating eight data sets are plotted as circles. Tri-
angles correspond to the five control genes used in [17] (NKI does not contain the ACTB gene).Page 6 of 10
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partially. After screening thousands of genes (generally
more than 10,000 genes in each data set), we have pro-
duced two separate lists of candidate genes: one specific to
breast cancer and one generally applicable to different
types of cancer. We do not consider these lists as generally
applicable, as the data used do not allow such generaliza-
tion. Different pathologies may have a different impact on
the control genes and some of the control genes we
selected may become ineffective in the case of a disease
which affects their particular functions. On the other
hand, more diverse data should be used if the goal is find-
ing global control genes. The list of the top 50 breast can-
cer control genes (Table 3) is dominated by ribosomal
proteins. This finding is consistent with the fact that ribos-
omes are a major component of basic physiologic proc-
esses in all the cells and not a primary target of changing
conditions. Other genes present among the first 50 genes
Table 3: Top 50 control genes as resulting from aggregating the ten breast cancer data sets. Two genes – RPS11 and UBB – were 
selected as control genes and validated by RT-PCR
Rank Gene symbol Gene ID Description
1 RPL37A 6168 ribosomal protein L37a
2 RPL27A 6157 ribosomal protein L27a
3 RPS18 6222 ribosomal protein S18
4 RPL30 6156 ribosomal protein L30
5 RPL41 6171 ribosomal protein L41
6 CALM2 805 calmodulin 2 (phosphorylase kinase, delta)
7 RPL27 6155 ribosomal protein L27
8 K-ALPHA-1 10376 alpha tubulin
9 RPS11 6205 ribosomal protein S11
10 RPL39 6170 ribosomal protein L39
11 RPS13 6207 ribosomal protein S13
12 NACA 4666 nascent-polypeptide-associated complex alpha polypeptide
12 RPL23A 6147 ribosomal protein L23a
14 RPS24 6229 ribosomal protein S24
15 HNRPA1 3178 heterogeneous nuclear ribonucleoprotein A1
16 RPL9 6133 ribosomal protein L9
17 RPLP1 6176 ribosomal protein, large, P1
18 RPL32 6161 ribosomal protein L32
19 LAPTM4A 9741 lysosomal-associated protein transmembrane 4 alpha
20 RPS15A 6210 ribosomal protein S15a
21 DYNLL1 8655 dynein, light chain, LC8-type 1
22 ACTG1 71 actin, gamma 1
23 TUBA6 84790 tubulin, alpha 6
24 SRP14 6727 signal recognition particle 14kDa (homologous Alu RNA binding protein)
25 MYL6 4637 myosin, light chain 6, alkali, smooth muscle and non-muscle
26 RPL24 6152 ribosomal protein L24
27 FAU 2197 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30
28 RPL31 6160 ribosomal protein L31
29 RPS15 6209 ribosomal protein S15
30 MTCH1 23787 mitochondrial carrier homolog 1 (C. elegans)
31 UBB 7314 ubiquitin B
32 RPL37 6167 ribosomal protein L37
33 HMGN2 3151 high-mobility group nucleosomal binding domain 2
34 RPS27 6232 ribosomal protein S27 (metallopanstimulin 1)
35 GDF8 2660 growth differentiation factor 8
36 RPL38 6169 ribosomal protein L38
37 RPS29 6235 ribosomal protein S29
38 SULT1C2 27233 sulfotransferase family, cytosolic, 1C, member 2
39 RPL6 6128 ribosomal protein L6
40 UBC 7316 ubiquitin C
41 UBA52 7311 ubiquitin A-52 residue ribosomal protein fusion product 1
42 MRFAP1 93621 Mof4 family associated protein 1
43 HNRPK 3190 heterogeneous nuclear ribonucleoprotein K
44 PARK7 11315 Parkinson disease (autosomal recessive, early onset) 7
45 PSMC1 5700 proteasome (prosome, macropain) 26S subunit, ATPase, 1
46 LOC158572 158572 hypothetical protein LOC158572
47 RPS8 6202 ribosomal protein S8
48 ATP5A1 498 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle
49 EIF4H 7458 eukaryotic translation initiation factor 4H
50 CD63 967 CD63 moleculePage 7 of 10
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proteins or actins, structures which are required in all liv-
ing cells.
Our results are supported by recent findings of de Jonge et
al. [5], who used a different ranking method. In addition,
the lists of control gene candidates for breast cancer and
for diverse types of cancer are similar [see Additional file
1 and Additional file 2], as a large number of the top
ranked genes belong to the same functional category
(ribosomal genes, protein turnover).
RT-QPCR experimentFigure 4
RT-QPCR experiment. Standard deviation as a function of the mean expression level (expressed as raw Ct values) of 47 
genes in a RT-QPCR experiment. Higher expression levels correspond to smaller raw Ct values. Control genes are repre-
sented by triangles, test genes by circles. The new control genes RPS11 and UBB are in the lower left corner.Page 8 of 10
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used control genes in breast cancer (ACTB and TFRC)
appear to be less stable than previously assumed. This has
an impact on the normalization strategy of the QPCR
measurements: indeed, in our more recent experiments
we have chosen to use the mean of RPLP0, RPS11 and
UBB (on the log2 scale) for normalizing the expression of
test genes.
Finally, we would like to emphasize that these two lists
should not be taken in an absolute sense: a gene in top 10
is not necessarily a better choice than a gene in the top 20
to 30. But we do consider it to be definitely a better candi-
date than a gene not in top 100. Nor do we consider the
resulting ranking as providing a solution to the problem
of finding normalization genes in all contexts. Rather, the
lists produced through this process are meant to guide the
choice of control genes while also taking into considera-
tion the specific requirements of any individual analysis.
Depending on the planned application, other parameters
must be considered. For example, short amplicons or
intron-spanning primers must be used when the starting
RNA is considerably degraded or when residual DNA con-
taminations might affect QPCR. The final choice of con-
trol genes should be made not by blind adherence to the
ranked list, but be imposed by the intended application.
Conclusion
Starting from clearly defined criteria, we have designed a
novel method for ranking the candidate genes for their
suitability as control genes in RT-QPCR experiments. The
genes from a data set were ranked according to their sta-
bility score, which represented a trade-off between gene's
average expression level and its variance. Finally, the rank-
ings from several data sets were combined into a list of
candidate genes, with higher ranked genes being consid-
ered to be more suitable as control genes. The proposed
approach had the advantage of being platform- and nor-
malization- independent and of not being restricted to
only the list of common genes across all data sets.
By applying the proposed method to two particular collec-
tions of data sets we were able to produce two lists of can-
didate genes from which control genes for either breast
cancer or more diverse cancer could be easily selected.
Two new control genes for breast cancer – UBB and RPS11
– have been identified and validated by RT-QPCR.
Our results support the hypothesis that selecting control
genes for QPCR from microarray data is feasible.
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